Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

15.89

Margin Of Safety %

Put/Call OI Ratio

0.66

EPS Next Q Diff

4.68

EPS Last/This Y

-4.54

EPS This/Next Y

5.5

Price

15.91

Target Price

28.42

Analyst Recom

2.86

Performance Q

-74.66

Relative Volume

0.86

Beta

0.45

Ticker: SRPT




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04SRPT18.20.460.34179797
2025-07-07SRPT17.340.460.90174836
2025-07-08SRPT19.030.470.19176796
2025-07-09SRPT19.360.470.38181624
2025-07-10SRPT19.060.460.56182681
2025-07-11SRPT18.170.470.39183063
2025-07-14SRPT19.230.470.25177715
2025-07-15SRPT18.220.470.29180101
2025-07-16SRPT18.50.471.87182090
2025-07-17SRPT220.480.50185605
2025-07-18SRPT14.060.501.64197740
2025-07-21SRPT13.290.641.71216502
2025-07-22SRPT13.620.721.17245242
2025-07-23SRPT13.30.760.66268159
2025-07-24SRPT12.910.740.97273489
2025-07-25SRPT11.910.741.11299866
2025-07-28SRPT13.850.720.57271473
2025-07-29SRPT15.850.720.78289647
2025-07-30SRPT16.730.680.28306628
2025-07-31SRPT16.440.670.37320874
2025-08-01SRPT15.890.660.48324750
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04SRPT18.24165.2250.4-1.89
2025-07-07SRPT17.34165.2246.7-1.89
2025-07-08SRPT19.03165.2257.2-1.89
2025-07-09SRPT19.37165.2251.5-1.89
2025-07-10SRPT19.07165.2249.1-1.89
2025-07-11SRPT18.17165.2245.7-1.89
2025-07-14SRPT19.23165.2254.4-1.89
2025-07-15SRPT18.21165.2246.3-1.89
2025-07-16SRPT18.39165.2250.9-1.89
2025-07-17SRPT21.97165.2264.3-1.89
2025-07-18SRPT14.08165.2223.0-1.89
2025-07-21SRPT13.30165.2-143.3-1.89
2025-07-22SRPT13.61165.2-157.7-1.89
2025-07-23SRPT13.32153.5-254.3-1.89
2025-07-24SRPT12.88153.5-251.5-1.89
2025-07-25SRPT11.93153.5-241.4-2.82
2025-07-28SRPT13.95153.5-300.1-2.82
2025-07-29SRPT15.83153.5-295.6-2.96
2025-07-30SRPT16.75164.0-275.5-2.96
2025-07-31SRPT16.42164.0-254.4-2.96
2025-08-01SRPT15.91164.0-251.3-2.20
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04SRPT-0.05-0.9810.58
2025-07-07SRPT-0.05-0.9810.58
2025-07-08SRPT-0.05-0.9810.58
2025-07-09SRPT-0.05-0.9810.58
2025-07-10SRPT-0.05-0.9810.58
2025-07-11SRPT-0.05-0.9815.71
2025-07-14SRPT-0.05-0.9015.71
2025-07-15SRPT-0.05-0.9015.71
2025-07-16SRPT-0.05-0.9015.71
2025-07-17SRPT-0.05-0.9015.71
2025-07-18SRPT-0.05-0.9015.71
2025-07-21SRPT-0.05-1.7615.71
2025-07-22SRPT-0.05-1.7615.71
2025-07-23SRPT-0.05-1.7615.71
2025-07-24SRPT-0.05-1.7615.71
2025-07-25SRPT-0.05-1.7615.89
2025-07-28SRPT-0.05-1.7515.89
2025-07-29SRPT-0.05-1.7515.89
2025-07-30SRPT-0.05-1.7515.89
2025-07-31SRPT-0.05-1.7515.89
2025-08-01SRPT-0.05-1.7515.89
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-4.6

Avg. EPS Est. Current Quarter

1.17

Avg. EPS Est. Next Quarter

0.08

Insider Transactions

-0.05

Institutional Transactions

-1.75

Beta

0.45

Average Sales Estimate Current Quarter

530

Average Sales Estimate Next Quarter

343

Fair Value

Quality Score

44

Growth Score

39

Sentiment Score

29

Actual DrawDown %

91.3

Max Drawdown 5-Year %

-93.3

Target Price

28.42

P/E

Forward P/E

7.43

PEG

P/S

0.7

P/B

1.37

P/Free Cash Flow

EPS

-2.58

Average EPS Est. Cur. Y​

-2.2

EPS Next Y. (Est.)

3.3

Target Price Estimates Raised

3

Target Price Estimates Lowered

Profit Margin

-11.12

Relative Volume

0.86

Return on Equity vs Sector %

-45.5

Return on Equity vs Industry %

-26.8

EPS 1 7Days Diff

0.6

EPS 1 30Days Diff

-0.31

EBIT Estimation

-251.3
Sarepta Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 1372
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today
news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance
stock history SRPT – Sarepta Therapeutics, Inc. invest stock market
stock prices SRPT premarket after hours
ticker SRPT fair value insiders trading